Skip to main content
OpenTrials
Completed

NCT Number: NCT01732263

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe hepatic (liver) impairment compared with subjects with healthy normal liver function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Clinical Pharmacology of Miami, Miami, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-65 years inclusive at the time of consent.
  • Willingness to comply with any applicable contraceptive requirements of the protocol and is:
  • Male, or
  • Non pregnant, non lactating female
  • Females must be at least 90 days post partum or nulliparous.

Subjects who do not have hepatic impairment (healthy subjects)

  • Normal renal function.

Subjects with hepatic impairment

  • Subjects must provide a letter of evaluation from a hepatologist or copy of supporting documents confirming the subject's hepatic impairment (a liver biopsy is preferable but not mandatory).
  • Hepatic impairment should be primary and must not be a complication of an underlying primary systemic disease (eg, patients with metastatic cancer and cancer cachexia)
  • Documented chronic stable liver impairment

Exclusion criteria

Subjects who do not have hepatic impairment (healthy subjects)

  • A positive HIV antibody screen, Hepatitis B surface antigen, or Hepatitis C virus antibody screen.

Subjects with hepatic impairment

  • Presence of a hepatocellular carcinoma, or an acute hepatic disease caused by an infection or drug toxicity.
  • Presence of surgically created or transjugular intrahepatic portal systemic shunts.
  • A positive HIV antibody screen.
  • Renal insufficiency.

All subjects

  • Subject has a history of thyroid disorder.
  • History of nephrotic syndrome.
  • History of alcohol or other substance abuse within the last year.
  • A positive screen for alcohol or drugs of abuse.
  • Male subjects who consume more than 3 units of alcohol per day. Female subjects who consume more than 2 units of alcohol per day. (1 alcohol unit = 1 beer [12 oz/355 mL] = 1 wine [5 oz/150 mL] = 1 liquor [1.5 oz/40 mL] = 0.75 oz/20 mL alcohol.)
  • Caffeine consumption: For healthy subjects: Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches or have a history of caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6 oz/180 mL cup of coffee, two 12 oz/355 mL (ie, 24 oz/710 mL cola) cans of cola, one 12 oz/355 mL cup of tea, three 1 oz/28 g chocolate bars (ie, 3 oz/85 g chocolate). Decaffeinated coffee, tea, or cola are not considered to contain caffeine.)
  • Donation of blood or blood products within 60 days.
  • Substantial changes in eating habits within 30 days.

Treatment and study plan

SSP-004184

Drug

All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1

Other names: SPD602, FBS0701

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184

    Time frame: Over 96 hours post-dose

    AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

  2. Maximum Plasma Concentration (Cmax) of SSP-004184

    Time frame: Over 96 hours post-dose

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

  3. Time of Maximum Plasma Concentration (Tmax) for SSP-004184

    Time frame: Over 96 hours post-dose

    Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

  4. Plasma Half-Life (T 1/2) of SSP-004184

    Time frame: Over 96 hours post-dose

    The time it takes for the blood plasma concentration of a substance to halve.

  5. Total Body Clearance (CL/F) of SSP-004184

    Time frame: Over 96 hours post-dose

    The rate at which a drug is removed from the body.

  6. Volume of Distribution (Vz/F) of SSP-004184

    Time frame: Over 96 hours post-dose

    The distribution of a medication between plasma and the rest of the body.

Sponsors and collaborators

Lead sponsor

Shire

Industry

Registry information

Official study title

A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Nov 22, 2012
Registry last updated
Jul 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.